報價延遲最少15分鐘:2024/11/10 18:48 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.90/0.15
|
|
企業價值
1.03B
|
| 資產負債 |
|
每股賬面淨值
0.31
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
202.09M
|
|
每股收益
2.93
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 18:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada. |